Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial

Journal of the American Medical Association

Volumn 285, Issue 11, 2001, Pages 1482-1488

  Alexandersen, Peter ^a   Toussaint, Anne ^a   Christiansen, Claus ^a   Devogelaer, Jean Pierre ^a   Roux, Christian ^a   Fechtenbaum, Jacques ^a   Gennari, Carlo ^a   Reginster, Jean Yves ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; HYDROXYPROLINE; IPRIFLAVONE;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROXYPROLINE URINE LEVEL; INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OUTCOMES RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN MANIFESTATION; URINARY TRACT DISEASE; VERTEBRA FRACTURE;

EID: 0035925780     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.11.1482     Document Type: Article

References (23)

1. The effect of ipriflavone (TC-80) on bone resorption in tissue culture
2. Inhibitory effect of ipriflavone on pit formation in mouse unfractionated bone cells
3. Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats
4. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line
5. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass
6. Ipriflavone prevents radial bone loss in postmenopausal with low bone mass over 2 years
7. Effect of ipriflavone - A synthetic derivative of natural isoflavones - On bone mass loss in the early years after menopause
8. Metabolicand clinical effects of ipriflavonen established post-menopausal osteoporosis
9. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass
10. Efficacy of ipriflavone in established osteoporosis and long-term safety
11. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss
12. New perspectives in the treatment of postmenopausal osteoporosis: Ipriflavone
13. Effect of ipriflavone on bone mass in elderly osteoporotic women
14. Design for an ipriflavone multicenter European fracture study
15. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment
16. Vertebral fracture assessment using a semiquantitative technique
17. Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state: Evaluation of two different dosage schemes
18. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
19. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
20. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
21. Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines
22. Drug-induced lymphopenia: Focus on CD4+ and CDS+ cells
23. Lymphocytopenia in a hospital population - What does it signify?